Salvinorin A, a kappa-opioid receptor agonist hallucinogen: Pharmacology and potential template for novel pharmacotherapeutic agents in neuropsychiatric disorders

Frontiers in Pharmacology

Volumn 6, Issue SEP, 2015, Pages

  Butelman, Eduardo R ^a   Kreek, Mary Jeanne ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Addiction; Depression; Dynorphins; Kappa opioid receptor; Salvia divinorum; Salvinorin A

Indexed keywords

BETA ARRESTIN; DYNORPHIN; KAPPA OPIATE RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; SALVINORIN A;

ADDICTION; ANXIETY DISORDER; CLINICAL EFFECTIVENESS; DOPAMINERGIC ACTIVITY; DOSE RESPONSE; DRUG ACTIVITY; ENZYME ACTIVATION; HUMAN; MOOD DISORDER; NEUROENDOCRINE SYSTEM; NONHUMAN; PSYCHOPATHY; SALVIA DIVINORUM; SHORT SURVEY; STRESS; TREATMENT RESPONSE; UPREGULATION;

EID: 84944723037     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2015.00190     Document Type: Short Survey

References (87)

1. Adams, D. H., Hanson, G. R., and Keefe, K. A. (2003). Distinct effects of methamphetamine and cocaine on preprodynorphin messenger RNA in rat striatal patch and matrix. J. Neurochem. 84, 87-93. doi: 10.1046/j.1471-4159.2003.01507.x
2. Adamson, W. T., Windh, R. T., Blackford, S., and Kuhn, C. M. (1991). Ontogeny of μ-and κ-opiate receptor control of the hypothalamo-pituitary-adrenal axis in rats. Endocrinology 129, 959-964. doi: 10.1210/endo-129-2-959
3. Addy, P. H. (2012). Acute and post-acute behavioral and psychological effects of salvinorin A in humans. Psychopharmacology (Berl.) 220, 195-204. doi: 10.1007/s00213-011-2470-6
4. Aldrich, J. V., Senadheera, S. N., Ross, N. C., Ganno, M. L., Eans, S. O., and Mclaughlin, J. P. (2013). The macrocyclic peptide natural product CJ-15,208 is orally active and prevents reinstatement of extinguished cocaine-seeking behavior. J. Nat. Prod. 76, 433-438. doi: 10.1021/np300697k
5. Baggott, M. J., Erowid, E., Erowid, F., Galloway, G. P., and Mendelson, J. (2010). Use patterns and self-reported effects of Salvia divinorum: an internet-based survey. Drug Alcohol. Depend. 111, 250-256. doi: 10.1016/j.drugalcdep.2010.05.003
6. Baker, L. E., Panos, J. J., Killinger, B. A., Peet, M. M., Bell, L. M., Haliw, L. A., et al. (2009). Comparison of the discriminative stimulus effects of salvinorin A and its derivatives to U69,593 and U50,488 in rats. Psychopharmacology (Berl.) 203, 203-211. doi: 10.1007/s00213-008-1458-3
7. Bart, G., Schluger, J. H., Borg, L., Ho, A., Bidlack, J. M., and Kreek, M. J. (2005). Nalmefene induced elevation in serum prolactin in normal human volunteers: partial κ-opioid agonist activity? Neuropsychopharmacology 30, 2254-2262. doi: 10.1038/sj.npp.1300811
8. Beardsley, P. M., Howard, J. L., Shelton, K. L., and Carroll, F. I. (2005). Differential effects of the novel kappa opioid receptor antagonist, JDTic, on reinstatement of cocaine-seeking induced by footshock stressors vs cocaine primes and its antidepressant-like effects in rats. Psychopharmacology (Berl.) 183, 118-126. doi: 10.1007/s00213-005-0167-4
9. Beguin, C., Potuzak, J., Xu, W., Liu-Chen, L. Y., Streicher, J. M., Groer, C. E., et al. (2012). Differential signaling properties at the kappa opioid receptor of 12-epi-salvinorin A and its analogues. Bioorg. Med. Chem. Lett. 22, 1023-1026. doi: 10.1016/j.bmcl.2011.11.128
10. Bidlack, J. M. (2014). Mixed κ-/μ partial opioid agonists as potential treatments for cocaine dependence. Adv. Pharmacol. 69, 387-418. doi: 10.1016/b978-0-12-420118-7.00010-x
11. Braida, D., Limonta, V., Capurro, V., Fadda, P., Rubino, T., Mascia, P., et al. (2008). Involvement of κ-opioid and endocannabinoid system on Salvinorin A-induced reward. Biol. Psychiatry 63, 286-292. doi: 10.1016/j.biopsych.2007.07.020
12. Bruchas, M. R., and Chavkin, C. (2010). Kinase cascades and ligand-directed signaling at the kappa opioid receptor. Psychopharmacology (Berl.) 210, 137-147. doi: 10.1007/s00213-010-1806-y
13. Bruchas, M. R., Land, B. B., and Chavkin, C. (2010). The dynorphin/κ-opioid system as a modulator of stress-induced and pro-addictive behaviors. Brain Res. 1314, 44-55. doi: 10.1016/j.brainres.2009.08.062
14. Butelman, E. R., Ball, J. W., and Kreek, M. J. (2004a). Peripheral selectivity and apparent efficacy of dynorphins: comparison to non-peptidic κ-opioid agonists in rhesus monkeys. Psychoneuroendocrinology 29, 307-326. doi: 10.1016/S0306-4530(03)00030-1
15. Butelman, E. R., Harris, T. J., and Kreek, M. J. (2004b). The plant-derived hallucinogen, salvinorin A, produces κ-opioid agonist-like discriminative effects in rhesus monkeys. Psychopharmacology (Berl.) 172, 220-224. doi: 10.1007/s00213-003-1638-0
16. Butelman, E. R., Caspers, M., Lovell, K. M., Kreek, M. J., and Prisinzano, T. E. (2012a). Behavioral effects and central nervous system levels of the broadly available κ-agonist hallucinogen salvinorin A are affected by P-glycoprotein modulation in vivo. J. Pharmacol. Exp. Ther. 341, 802-808. doi: 10.1124/jpet.112.193227
17. Butelman, E. R., Yuferov, V., and Kreek, M. J. (2012b). kappa opioid receptor/dynorphin system: genetic and pharmacotherapeutic implications for addiction. Trends Neurosci. 35, 587-596. doi: 10.1016/j.tins.2012.05.005
18. Butelman, E. R., Harris, T. J., and Kreek, M. (1999). Apparent efficacy of kappa-opioid receptor ligands on serum prolactin levels in rhesus monkeys. Eur. J. Pharmacol. 383, 305-309.
19. Butelman, E. R., Mandau, M., Tidgewell, K., Prisinzano, T. E., Yuferov, V., and Kreek, M. J. (2007). Effects of salvinorin A, a κ-opioid hallucinogen, on a neuroendocrine biomarker assay in nonhuman primates with high κ-receptor homology to humans. J. Pharmacol. Exp. Ther. 320, 300-306. doi: 10.1124/jpet.106.112417
20. Butelman, E. R., Prisinzano, T. E., Deng, H., Rus, S., and Kreek, M. J. (2009). Unconditioned behavioral effects of the powerful κ-opioid hallucinogen salvinorin A in nonhuman primates: fast onset and entry into cerebrospinal fluid. J. Pharmacol. Exp. Ther. 328, 588-597. doi: 10.1124/jpet.108.145342
21. Butelman, E. R., Rus, S., Prisinzano, T. E., and Kreek, M. J. (2010). The discriminative effects of the κ-opioid hallucinogen salvinorin A in nonhuman primates: dissociation from classic hallucinogen effects. Psychopharmacology (Berl.) 210, 253-262. doi: 10.1007/s00213-009-1771-5
22. Carlezon, W. A. Jr., Beguin, C., Dinieri, J. A., Baumann, M. H., Richards, M. R., Todtenkopf, M. S., et al. (2006). Depressive-like effects of the κ-opioid receptor agonist salvinorin A on behavior and neurochemistry in rats. J. Pharmacol. Exp. Ther. 316, 440-447. doi: 10.1124/jpet.105.092304
23. Chang, C., Byon, W., Lu, Y., Jacobsen, L. K., Badura, L. L., Sawant-Basak, A., et al. (2011). Quantitative PK-PD model-based translational pharmacology of a novel kappa opioid receptor antagonist between rats and humans. AAPS J. 13, 565-575. doi: 10.1208/s12248-011-9296-3
24. Chavkin, C. (2011). The therapeutic potential of κ-opioids for treatment of pain and addiction. Neuropsychopharmacology 36, 369-370. doi: 10.1038/npp.2010.137
25. Chavkin, C. (2012). Dynorphin-still an extraordinarily potent opioid peptide. Mol. Pharmacol. 83, 729-736. doi: 10.1124/mol.112.083337
26. Chavkin, C., and Goldstein, A. (1981). Specific receptor for the opioid peptide dynorphin: structure-activity relationships. Proc. Natl. Acad. Sci. U.S.A. 78, 6543-6547.
27. Chavkin, C., Sud, S., Jin, W., Stewart, J., Zjawiony, J. K., Siebert, D. J., et al. (2004). Salvinorin A, an active component of the hallucinogenic sage Salvia divinorum is a highly efficacious kappa-opioid receptor agonist: structural and functional considerations. J. Pharmacol. Exp. Ther. 308, 1197-1203. doi: 10.1124/jpet.103.059394
28. Cohen, A., Whitfield, T. W., Kreifeldt, M., Koebel, P., Kieffer, B. L., Contet, C., et al. (2014). Virus-mediated shRNA knockdown of prodynorphin in the rat nucleus accumbens attenuates depression-like behavior and cocaine locomotor sensitization. PLoS ONE 9:e97216. doi: 10.1371/journal.pone.0097216
29. Daunais, J. B., Roberts, D. C., and Mcginty, J. F. (1993). Cocaine self-administration increases preprodynorphin, but not c-fos, mRNA in rat striatum. Neuroreport 4, 543-546.
30. Dhawan, B. N., Cesselin, F., Raghubir, R., Reisine, T., Bradley, P. B., Portoghese, P. S., et al. (1996). International Union of Pharmacology. XII. Classification of opioid receptors. Pharmacol. Rev. 48, 567-592.
31. Di Chiara, G., and Imperato, A. (1988). Opposite effects of μ and κ-opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats. J. Pharmacol. Exp. Ther. 244, 1067-1080.
32. Fantegrossi, W. E., Kugle, K. M., Valdes, L. J. III., Koreeda, M., and Woods, J. H. (2005). kappa-opioid receptor-mediated effects of the plant-derived hallucinogen, salvinorin A, on inverted screen performance in the mouse. Behav. Pharmacol. 16, 627-633. doi: 10.1097/00008877-200512000-00005
33. Fantegrossi, W. E., Woods, J. H., and Winger, G. (2004). Transient reinforcing effects of phenylisopropylamine and indolealkylamine hallucinogens in rhesus monkeys. Behav. Pharmacol. 15, 149-157. doi: 10.1097/00008877-200403000-00007
34. Gehrke, B. J., Chefer, V. I., and Shippenberg, T. S. (2008). Effects of acute and repeated administration of salvinorin A on dopamine function in the rat dorsal striatum. Psychopharmacology (Berl.) 197, 509-517. doi: 10.1007/s00213-007-1067-6
35. Hooker, J. M., Xu, Y., Schiffer, W., Shea, C., Carter, P., and Fowler, J. S. (2008). Pharmacokinetics of the potent hallucinogen, salvinorin A in primates parallels the rapid onset and short duration of effects in humans. Neuroimage 41, 1044-1050. doi: 10.1016/j.neuroimage.2008.03.003
36. Johnson, M. W., Maclean, K. A., Reissig, C. J., Prisinzano, T. E., and Griffiths, R. R. (2011). Human psychopharmacology and dose-effects of salvinorin A, a κ-opioid agonist hallucinogen present in the plant Salvia divinorum. Drug Alcohol. Depend. 115, 150-155. doi: 10.1016/j.drugalcdep.2010.11.005
37. Killinger, B. A., Peet, M. M., and Baker, L. E. (2010). Salvinorin A fails to substitute for the discriminative stimulus effects of LSD or ketamine in Sprague-Dawley rats. Pharmacol. Biochem. Behav. 96, 260-265. doi: 10.1016/j.pbb.2010.05.014
38. Kivell, B., Uzelac, Z., Sundaramurthy, S., Rajamanickam, J., Ewald, A., Chefer, V., et al. (2014). Salvinorin A regulates dopamine transporter function via a kappa opioid receptor and ERK1/2-dependent mechanism. Neuropharmacology 86, 228-240. doi: 10.1016/j.neuropharm.2014.07.016
39. Ko, M. C., Butelman, E. R., Traynor, J. R., and Woods, J. H. (1998). Differentiation of κ-opioid agonist-induced antinociception by naltrexone apparent pA2 analysis in rhesus monkeys. J. Pharmacol. Exp. Ther. 285, 518-526.
40. Kreek, M. J., Schluger, J., Borg, L., Gunduz, M., and Ho, A. (1999). Dynorphin A1-13 causes elevation of serum levels of prolactin through an opioid receptor mechanism in humans: gender differences and implications for modulation of dopaminergic tone in the treatment of addictions. J. Pharmacol. Exp. Ther. 288, 260-269.
41. Kumor, K. M., Haertzen, C. A., Johnson, R. E., Kocher, T., and Jasinski, D. (1986). Human psychopharmacology of ketocyclazocine as compared with cyclazocine, morphine and placebo. J. Pharmacol. Exp. Ther. 238, 960-968.
42. Lange, J. E., Reed, M. B., Croff, J. M., and Clapp, J. D. (2008). College student use of Salvia divinorum. Drug Alcohol. Depend. 94, 263-266. doi: 10.1016/j.drugalcdep.2007.10.018
43. Li, J. X., Rice, K. C., and France, C. P. (2008). Discriminative stimulus effects of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane in rhesus monkeys. J. Pharmacol. Exp. Ther. 324, 827-833. doi: 10.1124/jpet.107.130625
44. Lovell, K. M., Frankowski, K. J., Stahl, E. L., Slauson, S. R., Yoo, E., Prisinzano, T. E., et al. (2015). Structure-activity relationship studies of functionally selective kappa opioid receptor agonists that modulate ERK 1/2 phosphorylation while preserving G protein over β-arrestin2 signaling bias. ACS Chem. Neurosci. 19, 1411-1419. doi: 10.1021/acschemneuro.5b00092
45. MacLean, K. A., Johnson, M. W., Reissig, C. J., Prisinzano, T. E., and Griffiths, R. R. (2013). Dose-related effects of salvinorin A in humans: dissociative, hallucinogenic, and memory effects. Psychopharmacology (Berl.) 226, 381-392. doi: 10.1007/s00213-012-2912-9
46. Mansour, A., Khachaturian, H., Lewis, M. E., Akil, H., and Watson, S. J. (1988). Anatomy of CNS opioid receptors. Trends Neurosci. 11, 308-314.
47. Mathieu-Kia, A. M., Fan, L. Q., Kreek, M. J., Simon, E. J., and Hiller, J. M. (2001). μ-, δ-and κ-opioid receptor populations are differentially altered in distinct areas of postmortem brains of Alzheimer's disease patients. Brain Res. 893, 121-134. doi: 10.1016/S0006-8993(00)03302-3
48. Mendelson, J. E., Coyle, J. R., Lopez, J. C., Baggott, M. J., Flower, K., Everhart, E. T., et al. (2011). Lack of effect of sublingual salvinorin A, a naturally occurring κ-opioid, in humans: a placebo-controlled trial. Psychopharmacology (Berl.) 214, 933-939. doi: 10.1007/s00213-010-2103-5
49. Negus, S. S., O'connell, R., Morrissey, E., Cheng, K., and Rice, K. C. (2012). Effects of peripherally restricted kappa opioid receptor agonists on pain-related stimulation and depression of behavior in rats. J. Pharmacol. Exp. Ther. 340, 501-509. doi: 10.1124/jpet.111.186783
50. Nestler, E. J., and Carlezon, W. A. Jr. (2006). The mesolimbic dopamine reward circuit in depression. Biol. Psychiatry 59, 1151-1159. doi: 10.1016/j.biopsych.2005.09.018
51. Neumeyer, J. L., Gu, X. H., Van Vliet, L. A., Denunzio, N. J., Rusovici, D. E., Cohen, D. J., et al. (2001). Mixed κ-agonists and μ agonists/antagonists as potential pharmacotherapeutics for cocaine abuse: synthesis and opioid receptor binding affinity of N-substituted derivatives of morphinan. Bioorg. Med. Chem. Lett. 11, 2735-2740. doi: 10.1016/S0960-894X(01)00543-1
52. Pande, A. C., Pyke, R. E., Greiner, M., Wideman, G. L., Benjamin, R., and Pierce, M. W. (1996). Analgesic efficacy of enadoline versus placebo or morphine in postsurgical pain. Clin. Neuropharmacol. 19, 451-456.
53. Pascoe, J. E., Williams, K. L., Mukhopadhyay, P., Rice, K. C., Woods, J. H., and Ko, M. C. (2008). Effects of μ, κ, and δ opioid receptor agonists on the function of hypothalamic-pituitary-adrenal axis in monkeys. Psychoneuroendocrinology 33, 478-486. doi: 10.1016/j.psyneuen.2008.01.006
54. Perron, B. E., Ahmedani, B. K., Vaughn, M. G., Glass, J. E., Abdon, A., and Wu, L. T. (2012). Use of Salvia divinorum in a nationally representative sample. Am. J. Drug Alcohol. Abuse 38, 108-113. doi: 10.3109/00952990.2011.600397
55. Pfeiffer, A., Brantl, V., Herz, A., and Emrich, H. M. (1986). Psychotomimesis mediated by κ-opiate receptors. Science 233, 774-776.
56. Prisinzano, T. E. (2013). Neoclerodanes as atypical opioid receptor ligands. J. Med. Chem. 56, 3435-3443. doi: 10.1021/jm400388u
57. Przekop, P., and Lee, T. (2009). Persistent psychosis associated with Salvia divinorum use. Am. J. Psychiatry 166, 832. doi: 10.1176/appi.ajp.2009.08121759
58. Ranganathan, M., Schnakenberg, A., Skosnik, P. D., Cohen, B. M., Pittman, B., Sewell, R. A., et al. (2012). Dose-related behavioral, subjective, endocrine, and psychophysiological effects of the κ-opioid agonist Salvinorin A in humans. Biol. Psychiatry. 72, 871-879. doi: 10.1016/j.biopsych.2012.06.012
59. Reed, B., Fang, N., Mayer-Blackwell, B., Chen, S., Yuferov, V., Zhou, Y., et al. (2012). Chromatin alterations in response to forced swimming underlie increased prodynorphin transcription. Neuroscience 220, 109-118. doi: 10.1016/j.neuroscience.2012.06.006
60. Riley, A. P., Groer, C. E., Young, D., Ewald, A. W., Kivell, B. M., and Prisinzano, T. E. (2014). Synthesis and kappa opioid receptor activity of furan-substituted Salvinorin A analogues. J. Med. Chem. 57, 10464-10475. doi: 10.1021/jm501521d
61. Rorick-Kehn, L. M., Witkin, J. M., Statnick, M. A., Eberle, E. L., Mckinzie, J. H., Kahl, S. D., et al. (2014). LY2456302 is a novel, potent, orally-bioavailable small molecule κ-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders. Neuropharmacology 77, 131-144. doi: 10.1016/j.neuropharm.2013.09.021
62. Roth, B. L., Baner, K., Westkaemper, R., Siebert, D., Rice, K. C., Steinberg, S., et al. (2002). Salvinorin A: a potent naturally occurring nonnitrogenous κ-opioid selective agonist. Proc. Natl. Acad. Sci. U.S.A. 99, 11934-11939. doi: 10.1073/pnas.182234399
63. Serra, V., Fattore, L., Scherma, M., Collu, R., Spano, M. S., Fratta, W., et al. (2015). Behavioural and neurochemical assessment of salvinorin A abuse potential in the rat. Psychopharmacology (Berl). 232, 91-100. doi: 10.1007/s00213-014-3641-z
64. Siebert, D. (1994). Salvia divinorum and salvinorin A: new pharmacologic findings. J. Ethnopharmacol. 43, 53-56.
65. Simonin, F., Gaveriaux-Ruff, C., Befort, K., Matthes, H., Lannes, B., Micheletti, G., et al. (1995). kappa-Opioid receptor in humans: cDNA and genomic cloning, chromosomal assignment, functional expression, pharmacology, and expression pattern in the central nervous system. Proc. Natl. Acad. Sci. U.S.A. 92, 7006-7010.
66. Simonson, B., Morani, A. S., Ewald, A. W., Walker, L., Kumar, N., Simpson, D., et al. (2014). Pharmacology and anti-addiction effects of the novel kappa opioid receptor agonist Mesyl Sal B, a potent and long-acting analogue of salvinorin A. Br. J. Pharmacol. 172, 515-531. doi: 10.1111/bph.12692
67. Singh, S. (2007). Adolescent salvia substance abuse. Addiction 102, 823-824. doi: 10.1111/j.1360-0443.2007.01810.x
68. Spanagel, R., Herz, A., and Shippenberg, T. S. (1990). The effects of opioid peptides on dopamine release in the nucleus accumbens: an in vivo microdialysis study. J. Neurochem. 55, 1734-1740.
69. Spangler, R., Unterwald, E. M., and Kreek, M. J. (1993). 'Binge' cocaine administration induces a sustained increase of prodynorphin mRNA in rat caudate-putamen. Brain Res. Mol. Brain Res. 19, 323-327.
70. Tejeda, H. A., Shippenberg, T. S., and Henriksson, R. (2012). The dynorphin/kappa-opioid receptor system and its role in psychiatric disorders. Cell. Mol. Life. Sci. 69, 857-896. doi: 10.1007/s00018-011-0844-x
71. Unterwald, E. M., Rubenfeld, J. M., and Kreek, M. J. (1994). Repeated cocaine administration upregulates kappa and mu, but not delta, opioid receptors. Neuroreport 5, 1613-1616.
72. Ur, E., Wright, D. M., Bouloux, P. M., and Grossman, A. (1997). The effects of spiradoline (U-62066E), a kappa-opioid receptor agonist, on neuroendocrine function in man. Br. J. Pharmacol. 120, 781-784. doi: 10.1038/sj.bjp.0700971
73. Valdes, L. J., 3rd, Diaz, J. L., and Paul, A. G. (1983). Ethnopharmacology of ska Maria Pastora (Salvia divinorum, Epling and Jativa-M.). J. Ethnopharmacol. 7, 287-312.
74. Valle, M., Maqueda, A., Bouso, J. C., Puntes, M., Ballester, M. R., Garrido, M., et al. (2014). Naltrexone inhibits the subjective effects of salvinorin-A in humans. Drug Alcohol. Depend. 146, e9. doi: 10.1016/j.drugalcdep.2014.09.706
75. Walsh, S. L., Chausmer, A. E., Strain, E. C., and Bigelow, G. E. (2008). Evaluation of the μ and κ-opioid actions of butorphanol in humans through differential naltrexone blockade. Psychopharmacology (Berl.) 196, 143-155. doi: 10.1007/s00213-007-0948-z
76. Walsh, S. L., Geter-Douglas, B., Strain, E. C., and Bigelow, G. E. (2001). Enadoline and butorphanol: evaluation of κ-agonists on cocaine pharmacodynamics and cocaine self-administration in humans. J. Pharmacol. Exp. Ther. 299, 147-158.
77. Wang, X. M., Zhou, Y., Spangler, R., Ho, A., Han, J. S., and Kreek, M. J. (1999). Acute intermittent morphine increases preprodynorphin and kappa opioid receptor mRNA levels in the rat brain. Brain Res. Mol. Brain Res. 66, 184-187.
78. Wang, Y., Chen, Y., Xu, W., Lee, D. Y., Ma, Z., Rawls, S. M., et al. (2008). 2-Methoxymethyl-salvinorin B is a potent kappa opioid receptor agonist with longer lasting action in vivo than salvinorin A. J. Pharmacol. Exp. Ther. 324, 1073-1083. doi: 10.1124/jpet.107.132142
79. White, K. L., Robinson, J. E., Zhu, H., Diberto, J. F., Polepally, P. R., Zjawiony, J. K., et al. (2015). The G protein-biased kappa-opioid receptor agonist RB-64 is analgesic with a unique spectrum of activities in vivo. J. Pharmacol. Exp. Ther. 352, 98-109. doi: 10.1124/jpet.114.216820
80. White, K. L., Scopton, A. P., Rives, M. L., Bikbulatov, R. V., Polepally, P. R., Brown, P. J., et al. (2014). Identification of novel functionally selective kappa-opioid receptor scaffolds. Mol. Pharmacol. 85, 83-90. doi: 10.1124/mol.113.089649
81. Whitfield, T. W. Jr., Schlosburg, J. E., Wee, S., Gould, A., George, O., Grant, Y., et al. (2015). kappa Opioid receptors in the nucleus accumbens shell mediate escalation of methamphetamine intake. J. Neurosci. 35, 4296-4305. doi: 10.1523/jneurosci.1978-13.2015
82. Wu, L. T., Woody, G. E., Yang, C., Li, J. H., and Blazer, D. G. (2011). Recent national trends in Salvia divinorum use and substance-use disorders among recent and former Salvia divinorum users compared with nonusers. Subst Abuse Rehabil 2011, 53-68. doi: 10.2147/sar.s17192
83. Zhang, H., Shi, Y. G., Woods, J. H., Watson, S. J., and Ko, M. C. (2007). Central kappa-opioid receptor-mediated antidepressant-like effects of nor-Binaltorphimine: behavioral and BDNF mRNA expression studies. Eur. J. Pharmacol 570, 89-96. doi: 10.1016/j.ejphar.2007.05.045
84. Zhang, Y., Butelman, E. R., Schlussman, S. D., Ho, A., and Kreek, M. J. (2004). Effect of the endogenous κ-opioid agonist dynorphin A (1-17) on cocaine-evoked increases in striatal dopamine levels and cocaine-induced place preference in C57BL/6J mice. Psychopharmacology (Berl.) 172, 422-429. doi: 10.1007/s00213-003-1688-3
85. Zhang, Y., Butelman, E. R., Schlussman, S. D., Ho, A., and Kreek, M. J. (2005). Effects of the plant-derived hallucinogen salvinorin A on basal dopamine levels in the caudate putamen and in a conditioned place aversion assay in mice: agonist actions at kappa opioid receptors. Psychopharmacology (Berl.) 179, 551-558. doi: 10.1007/s00213-004-2087-0
86. Zhou, L., Lovell, K. M., Frankowski, K. J., Slauson, S. R., Phillips, A. M., Streicher, J. M., et al. (2013a). Development of functionally selective, small molecule agonists at kappa opioid receptors. J. Biol. Chem. 288, 36703-36716. doi: 10.1074/jbc.M113.504381
87. Zhou, Y., Leri, F., Grella, S., Aldrich, J., and Kreek, M. J. (2013b). Involvement of dynorphin and kappa opioid receptor in yohimbine-induced reinstatement of heroin seeking in rats. Synapse 67, 358-361. doi: 10.1002/syn.21638